WO1998009668A3 - Inhibiteurs de la synthese de la phosphatidylcholine - Google Patents
Inhibiteurs de la synthese de la phosphatidylcholine Download PDFInfo
- Publication number
- WO1998009668A3 WO1998009668A3 PCT/GB1997/002410 GB9702410W WO9809668A3 WO 1998009668 A3 WO1998009668 A3 WO 1998009668A3 GB 9702410 W GB9702410 W GB 9702410W WO 9809668 A3 WO9809668 A3 WO 9809668A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amphiphiles
- phosphatidyl choline
- synthesis inhibitors
- amphiphilic compound
- group
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000129 anionic group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000005192 partition Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65848—Cyclic amide derivatives of acids of phosphorus, in which two nitrogen atoms belong to the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU41285/97A AU4128597A (en) | 1996-09-06 | 1997-09-08 | Phosphatidylcholine synthesis inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9618634.1A GB9618634D0 (en) | 1996-09-06 | 1996-09-06 | Anti cancer drugs |
GB9618634.1 | 1996-09-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998009668A2 WO1998009668A2 (fr) | 1998-03-12 |
WO1998009668A3 true WO1998009668A3 (fr) | 1998-06-25 |
Family
ID=10799530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/002410 WO1998009668A2 (fr) | 1996-09-06 | 1997-09-08 | Inhibiteurs de la synthese de la phosphatidylcholine |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4128597A (fr) |
GB (1) | GB9618634D0 (fr) |
WO (1) | WO1998009668A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
US7205404B1 (en) | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
EP1634886A3 (fr) * | 1999-03-05 | 2006-03-29 | Metabasis Therapeutics, Inc. | Nouveaux promedicaments a teneur en phosphore |
AU775332B2 (en) * | 1999-03-05 | 2004-07-29 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing prodrugs |
WO2001018013A1 (fr) | 1999-09-08 | 2001-03-15 | Metabasis Therapeutics, Inc. | Promedicaments destines a l'administration specifique de medicaments au foie |
KR20010082102A (ko) * | 2000-02-14 | 2001-08-29 | 다나까 모또아끼 | 4 차 암모늄염의 제조 방법 |
WO2001071022A2 (fr) * | 2000-03-17 | 2001-09-27 | The University Of Tennessee Research Corporation | Agonistes et antagonistes du recepteur lpa et procedes d'utilisation de ces derniers |
FR2818547B1 (fr) | 2000-12-22 | 2006-11-17 | Oreal | Nouveaux derives c-glycosides et utilisation |
FR2818646B1 (fr) * | 2000-12-22 | 2006-06-23 | Oreal | Nouveaux derives c-glycoside et utilisation |
CA2937548C (fr) | 2014-02-13 | 2022-10-25 | Ligand Pharmaceuticals, Inc. | Composes de promedicaments et leurs utilisations |
JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
AU2019207625A1 (en) | 2018-01-09 | 2020-07-30 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
CN112480036A (zh) * | 2020-12-02 | 2021-03-12 | 天津理工大学 | 一种哌啶类离子液体表面活性剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0108565A2 (fr) * | 1982-11-08 | 1984-05-16 | Takeda Chemical Industries, Ltd. | Phospholipides, leur production et leur utilisation |
JPS60178816A (ja) * | 1984-02-24 | 1985-09-12 | Rikagaku Kenkyusho | 制癌剤 |
-
1996
- 1996-09-06 GB GBGB9618634.1A patent/GB9618634D0/en active Pending
-
1997
- 1997-09-08 AU AU41285/97A patent/AU4128597A/en not_active Abandoned
- 1997-09-08 WO PCT/GB1997/002410 patent/WO1998009668A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0108565A2 (fr) * | 1982-11-08 | 1984-05-16 | Takeda Chemical Industries, Ltd. | Phospholipides, leur production et leur utilisation |
JPS60178816A (ja) * | 1984-02-24 | 1985-09-12 | Rikagaku Kenkyusho | 制癌剤 |
Non-Patent Citations (24)
Title |
---|
ATTARD, G.S. ET AL: "Phase behaviour of novel phospholipid comounds", CHEMISTRY AND PHYSICS OF LIPIDS, vol. 76, no. 1, 1995, pages 41 - 48, XP002061928 * |
BECKERS, D. ET AL: "Molecular targets of Miltefosine", DRUGS OF TODAY, vol. 30, no. suppl. B, 1994, pages 5 - 12, XP002046737 * |
BOGGS, KEVIN P. ET AL: "Lysophosphatidylcholine and 1-O-Octadecyl-2-O-Methyl-rac-Glycero-3-Phosphocholine inhibit the CDP-Choline pathway of phosphatidylcholine synthesis at the CTP:Phosphocholine Cytidylyltransferase step", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 13, 31 March 1995 (1995-03-31), pages 7757 - 7764, XP002061925 * |
BOURNE RK: "CHEMICAL SYNTHESIS AND ANTITUMOR ACTIVITY OF PHOSPHOGLYCERIDE MUSTARDS.", DISS ABSTR INT (SCI);37(5):2261-B-2262-B 1976, XP002061935 * |
COY, E.A. ET AL: "Antiproliferative effects of amphiphilic molecules", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, vol. 12, no. 8, 1990, pages 871 - 881, XP002061930 * |
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TAKAHASHI, N. ET AL: "Anticancer pharmaceuticals containing surfactants as active ingredients" * |
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002061940 * |
DATABASE WPI Week 8543, Derwent World Patents Index; AN 85-266689, XP002046739 * |
DELLINGER, M. ET AL: "Structural requirements of simple organic cations for recognition by multidrug resistant cells", CANCER RESEARCH, vol. 52, no. 22, 15 November 1992 (1992-11-15), pages 6385 - 6389, XP002061932 * |
DICK D L ET AL: "PHYSICOCHEMICAL BEHAVIOR OF CYTOTOXIC ETHER LIPIDS", BIOCHEMISTRY, 31 (35). 1992. 8252-8257., XP002061929 * |
GEILEN, C.C. ET AL: "Phosphatidylcholine biosynthesis as a target for phospholipid analogues", ADV.EXP.MED.BIOL. (PLATELET-ACTIVATING FACTOR AND RELATED LIPID MEDIATORS 2), vol. 416, 1996, pages 333 - 336, XP002061924 * |
HILLYARD, L.A. ET AL: "Membrane proliferation and phosphatidylcholine synthesis in normal, preneoplastic and neoplastic mammary gland tissues in C3H mice", CANCER RESEARCH, vol. 32, no. 12, 1972, pages 2834 - 2842, XP002061936 * |
KELLEY, E.E. ET AL: "Unidirectional membrane uptake of the ether lipid antineoplastic agent Edelfosine by L1210 cells", BIOCHEMICAL PHARMACOLOGY, vol. 45, no. 2, 1993, pages 2435 - 2439, XP002046738 * |
KUCZERA, J. ET AL: "Effects of some cyclic elements containing amphiphilic compounds on stability and transport properties of model lecithin membranes", GENERAL PHYSIOLOGY AND BIOPHYSICS, vol. 6, no. 6, December 1987 (1987-12-01), pages 645 - 654, XP002061939 * |
LOE, D.W. ET AL: "Interaction of multidrug-resistant Chinese hamster ovary cells with amphiphiles", BRITISH JOURNAL OF CANCER, vol. 68, no. 2, 1993, pages 342 - 351, XP002061931 * |
MACKENZIE, A.N.: "The synthesis of novel phospholipids (HIV-1, immune deficiency, antineoplastic agents).", DISSERTATION ABSTRACTS INTERNATIONAL, vol. 57, no. 3-C, 1995, pages 947, XP002061927 * |
MATSUMOTO, Y. ET AL: "Specific hybrid liposomes composed of phosphatidylcholine and polyoxyethylenealkyl ether with markedly enhanced imnhibitory effects on the growth of tumor cells in vitro", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 18, no. 10, October 1995 (1995-10-01), pages 1456 - 8, XP000537683 * |
NISHISAKI, H. ET AL: "Inhibitory effects of antitumor drugs on phosphatidylcholine synthesis and its reversal by teprenone in isolated guinea pig gastric glands", IGAKU NO AYUMI, vol. 155, no. 10, 1990, pages 669 - 670 * |
PLANTAVID M ET AL: "CATIONIC AMPHIPHILIC DRUGS AS A POTENTIAL TOOL FOR MODIFYING PHOSPHOLIPIDS OF TUMOR CELLS. AN IN VITRO STUDY OF CHLORPROMAZINE EFFECTS ON KREBS II ASCITES CELLS", BIOCHEM PHARMACOL;30(4):293-297 1981, XP002061926 * |
RAYNOR R.L. ET AL: "Membrane interactions of amphiphilic polypeptides mastoparan, melittin, polymyxin B, and cardiotoxin", J. BIOL. CHEM., 1991, 266/5 (2753-2758), USA, XP002061934 * |
READ, GEORGE W. ET AL: "Competitive inhibition of 48/80-induced histamine release by benzalkonium chloride and its analogs and the polyamine receptor in mast cells", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 222, no. 3, 1982, pages 652 - 7, XP002061938 * |
ROTENBERG, S.A. ET AL: "Inhibition of rodent protein kinase C by the anticarcinoma agent dequalinium", CANCER RESEARCH, vol. 50, no. 3, 1990, pages 677 - 685, XP002061933 * |
WIEDER,T. ET AL: "The effect of two synthetic phospholipids on cell proliferation and phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells", LIPIDS, vol. 30, no. 5, 1995, pages 389 - 393, XP002061923 * |
WOOD, S.J. ET AL: "Selective inhibition of A.beta fibril formation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 8, 23 February 1996 (1996-02-23), pages 4086 - 4092, XP002061937 * |
Also Published As
Publication number | Publication date |
---|---|
GB9618634D0 (en) | 1996-10-16 |
WO1998009668A2 (fr) | 1998-03-12 |
AU4128597A (en) | 1998-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998009668A3 (fr) | Inhibiteurs de la synthese de la phosphatidylcholine | |
CA2270887A1 (fr) | Methodes et compositions visant a l'inhibition de l'angiogenese | |
CA2192433A1 (fr) | Composes anti-herpesvirus et methodes de caracterisation, de production et d'utilisation | |
CA2338252A1 (fr) | Composition permettant d'ameliorer la production lipidique, la fonction de barriere, la neutralisation du peroxyde d'hydrogene et l'hydratation de la peau | |
US5627171A (en) | Sphingosine-1-phosphate/trimethylsphingosine composition | |
CA2228256A1 (fr) | Ouate de cellulose enduite d'une lotion contenant un emollient et un polyol polyester | |
AU5165393A (en) | Substituted benzylaminoquinuclidines as substance p antagonists | |
CA2192179A1 (fr) | Papier de soie traite avec une lotion | |
CA2342974A1 (fr) | Methodes et compositions pour l'inhibition de l'angiogenese | |
MX9908953A (es) | Productos nutricionales que contienen oligosacaridos. | |
CA2371881A1 (fr) | Composition emulsionnee huile dans eau acide | |
AU3780497A (en) | Improvements in or relating to contrast agents | |
AU572228B2 (en) | Phosphatidyl serine compositions for cns disorders | |
WO1999048462A3 (fr) | Procede de nettoyage de surfaces d'aluminium | |
EP0391162A3 (fr) | Systèmes de polyols et de silicones à fonctions époxy durcissables par rayonnement ultraviolet | |
MX9606330A (es) | Composicion inhibidora de corrosion para acero. | |
HK1033280A1 (en) | Compositions for increasing the concentration and/or motility of spermatozoa in humans. | |
Silvola et al. | Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity | |
CA2321658A1 (fr) | Composition desinfectante | |
CA2217710A1 (fr) | Substance anticancereuse inhibant les metastases cancereuses | |
CA2320878A1 (fr) | Microgranules de sulfate de morphine, procede de fabrication et preparations pharmaceutiques | |
WO1998053800A8 (fr) | Compositions et procedes destines a empecher les adherences | |
AU5710696A (en) | Platelet aggregation inhibitors | |
WO2003039506A3 (fr) | Preparations cosmetiques et dermatologiques a protection solaire contenant des hydroxybenzophenones et des alkyle naphtalates | |
AU3382697A (en) | Dihydrobenzopyran and related compounds useful as anti-inflammatory agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998512375 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |